3SBio and Alexandria Venture Investments have both contributed to a $50m round raised by Verseau, which is developing immunotherapies based on MIT research.
Verseau Therapeutics, a US-based cancer immunotherapy spinout of Massachusetts Institute of Technology, launched with $50m in funding yesterday from investors including biotechnology producer 3SBio and life sciences real estate investment trust Alexandria Real Estate Equities.
The round also featured 20/20 HealthCare Partners, Highlight Capital, Yonghua Capital, InHarv Partners and Mark Foundation for Cancer Research, while Alexandra Real Estate Equities participated through its Alexandria Venture Investments unit.
Founded in 2017, Verseau is working on immunotherapies that reprogram macrophages – large…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
